Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia

Leukemia. 2004 Nov;18(11):1907-9. doi: 10.1038/sj.leu.2403502.

Authors

D-W Kim, Y-J Chung, S Lee, Y-J Kim, N-G Chung, J A Kim, I-H Oh, T-G Kim, Y-L Kim, H-G Goh, S-H Kim, B Cho, H-J Kim, C-K Min, J W Lee, J Y Jin, C-W Han, J W Kim, W-S Min, H-K Kim, C-C Kim, H J Kim

PMID: 15356641
DOI: 10.1038/sj.leu.2403502

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Benzamides
Female
Graft vs Host Disease / etiology
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
Male
Middle Aged
Morbidity
Piperazines / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / therapeutic use*
Stem Cell Transplantation*
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases